Ahrari, S., Tooqian Chaharsoughi, N., Basiri Moghaddam, M., Khodadoust, Sh., & Mohtasham, F. (2015). Determining the relationship between depression and adherence to therapeutic regimens in patients with type 2 diabetes referred to 22 Bahman Hospital in Gonabad.DOI:
10.1001/archinte.160.21.3278
Alosaimi, F. D., AlMulhem, A., AlShalan, H., Alqazlan, M., Aldaif, A., Kowgier, M., Balasundaram, J., & Sockalingam, S. (2017). Psychosocial predictors of patient adherence to disease-modifying therapies for multiple sclerosis.
Patient preference and adherence, 513-518. DOI:
10.2147/PPA.S129678
Anderson, L. J., Nuckols, T. K., Coles, C., Le, M. M., Schnipper, J. L., Shane, R., Jackevicius, C., Lee, J., Pevnick, J. M., & PHARM-DC Group Choudhry Niteesh K MD, P. D. O. M. D. M. S. C. M. (2020). A systematic overview of systematic reviews evaluating medication adherence interventions.
American Journal of Health-System Pharmacy,
77(2), 138-147. DOI:
10.1093/ajhp/zxz284
Arroyo, E., Grau, C., Ramo, C., Parra, J., & Sánchez-Soliño, O. (2010). Global adherence project to disease-modifying therapies in patients with relapsing multiple sclerosis: 2-year interim results. Neurología (English Edition), 25(7), 435-442. PMID: 20964990
Basso, M. R., Shields, I. S., Lowery, N., Ghormley, C., Combs, D., Arnett, P. A., & Johnson, J. (2008). Self-reported executive dysfunction, neuropsychological impairment, and functional outcomes in multiple sclerosis.
Journal of Clinical and Experimental Neuropsychology,
30(8),920-930.DOI:
10.1080/13803390801888733
Bertolin, D. C., Pace, A. E., Cesarino, C. B., Ribeiro, R. d. C. H. M., & Ribeiro, R. M. (2015). Psychological adaptation to and acceptance of type 2 diabetesmellitus.
ACTA Paulista de Enfermagem,
28, 440-446. DOI:
10.1590/1982-0194201500074
Boeschoten, R. E., Braamse, A. M., Beekman, A. T., Cuijpers, P., van Oppen, P., Dekker, J., & Uitdehaag, B. M. (2017). Prevalence of depression and anxiety in multiple sclerosis: a systematic review and meta-analysis. Journal of the neurological sciences, 372, 331-341. Doi: 10.1016/j.jns.2016.11.067
Browne, P., Chandraratna, D., Angood, C., Tremlett, H., Baker, C., Taylor, B. V., & Thompson, A. J. (2014). Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity.
Neurology,
83(11), 1022-1024. doi:
10.1212/WNL.000000000000076
Bruce, J. M., Hancock, L. M., Arnett, P., & Lynch, S. (2010). Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition.
Journal of behavioral medicine,
33, 219-227. DOI:
10.1007/s10865-010-9247-y
Burkhard, A., Toliver, J., & Rascati, K. (2021). Association between multiple sclerosis disease severity and adherence to disease-modifying therapies.
Journal of managed care & specialty pharmacy,
27(7), 915-923. DOI:
10.18553/jmcp.2021.27.7.915
Burks, J., Marshall, T. S., & Ye, X. (2017). Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis.
ClinicoEconomics and outcomes research, 251-260. DOI:
10.2147/CEOR.S130334
Calabrese, P. (2006). Neuropsychology of multiple sclerosis: An overview.
Journal of neurology,
253, i10-i15. DOI:
10.1007/s00415-006-1103-1
Cerezo García, M., Martín Plasencia, P., & Aladro Benito, Y. (2015). Alteration profile of executive functions in multiple sclerosis.
Acta Neurologica Scandinavica,
131(5), 313-320. DOI:
10.1111/ane.12345
Cerezo García, M., Martín Plasencia, P., Aladro Benito, Y., Balseiro Gómez, J. J., & Rueda Marcos, A. (2009). Executive function and memory in patients with relapsing-remitting multiple sclerosis. Psicothema, 21(3), 416-420. PMID: 19622322
Clerico, M., Barbero, P., Contessa, G., Ferrero, C., & Durelli, L. (2007). Adherence to interferon-beta treatment and results of therapy switching.
Journal of the neurological sciences,
259(1-2), 104-108. DOI:
10.1016/j.jns.2006.05.075
Cox, D., & Stone, J. (2006). Managing self–injection difficulties in patients with relapsing–remitting multiple sclerosis.
Journal of Neuroscience Nursing,
38(3), 167-171. DOI:
10.1097/01376517-200606000-00005
Devonshire, V., Lapierre, Y., Macdonell, R., Ramo‐Tello, C., Patti, F., Fontoura, P., Suchet, L., Hyde, R., Balla, I., & Frohman, E. (2011). The Global Adherence Project (GAP): A multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosis.
European Journal of Neurology,
18(1), 69-77. DOI:
10.1111/j.1468-1331.2010.03110.x
Drew, M., Tippett, L. J., Starkey, N. J., & Isler, R. B. (2008). Executive dysfunction and cognitive impairment in a large community-based sample with Multiple Sclerosis from New Zealand: a descriptive study.
Archives of clinical neuropsychology,
23(1), 1-19. DOI:
10.1016/j.acn.2007.09.005
Deyyanti, Mansour, Nejad, M., & Taghaddosi. (2019). Examining medication adherence and its related factors in patients with coronary artery syndrome during the post-discharge period from Beheshti Hospital in Kashan in 2017. Feyz Journal of Kashan University of Medical Sciences, 23(2), 201,208. doi
10.1186/s12955-018-0921-z
Fiest, K., Walker, J., Bernstein, C., Graff, L., Zarychanski, R., Abou-Setta, A., Patten, S., Sareen, J., Bolton, J., & Marriott, J. (2016). Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis.
Multiple sclerosis and related disorders,
5, 12-26. DOI:
10.1016/j.msard.2015.10.004
Foong, J., Rozewicz, L., Quaghebeur, G., Davie, C., Kartsounis, L., Thompson, A., Miller, D., & Ron, M. (1997). Executive function in multiple sclerosis. The role of frontal lobe pathology.
Brain: a journal of neurology,
120(1), 15-26. DOI:
10.1093/brain/120.1.15
Godefroy, O., Azouvi, P., Robert, P., Roussel, M., LeGall, D., Meulemans, T., & Group, B. o. t. G. d. R. s. l. E. d. F. E. S. (2010). Dysexecutive syndrome: diagnostic criteria and validation study.
Annals of neurology,
68(6), 855-864. DOI:
10.1002/ana.22117
Guzik, A., & Kwolek, A. (2015). Częstość występowania i rozmieszczenie stwardnienia rozsianego w Polsce i na świecie.
Ghashlaq, G., Abadi, Abbas, Raygani, V., Tabrizi, N., Kian, Dalvandi, Mahmoudi, & Hasan. (2015). Determining the criterion validity of the Morisky Medication Adherence Scale in type 2 diabetic patients. Journal of Rehabilitation Nursing Research, 1(3), 24–32.
http://ijrn.ir/article-1-98-en.html
Henry, A., Tourbah, A., Camus, G., Deschamps, R., Mailhan, L., Castex, C., Gout, O., & Montreuil, M. (2019). Anxiety and depression in patients with multiple sclerosis: The mediating effects of perceived social support.
Multiple sclerosis and related disorders,
27, 46-51. DOI:
10.1016/j.msard.2018.09.039
Horne, R., & Weinman, J. (2020). Predicting treatment adherence: an overview of theoretical models. Adherance to Treatment in Medical Conditions, 25-50.
Husseini, Z., Nejati, V., & Habibi, M. (2019). The Relationship between Poor Executive Functioning and Social Functioning and the Efficacy of Brain Training on Social Functioning. Journal of Rehabilitation Sciences & Research, 6(2), 95-100.
Ivanova, J., Bergman, R., Birnbaum, H., Phillips, A., Stewart, M., & Meletiche, D. (2012). Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US.
Journal of medical economics,
15(3), 601-609. DOI:
10.3111/13696998.2012.667027
Jackson-Koku, G. (2016). Beck depression inventory.
Occupational medicine,
66(2), 174-175. DOI:
10.1093/occmed/kqv087
Khalili, F., Eslami, A. A., Farajzadegan, Z., & Hasan Zadeh, A. (2011). Investigating the relationship between some psychosocial factors and adherence behaviors to treatment in hemodialysis patients in Isfahan: A conceptual framework based on the social-cognitive theory.
http://unmf.umsu.ac.ir/article-1-3071-en.html
Kołtuniuk, A., & Rosińczuk, J. (2021). The levels of depression, anxiety, acceptance of illness, and medication adherence in patients with multiple sclerosis-descriptive and correlational study.
International journal of medical sciences,
18(1), 216. DOI:
10.7150/ijms.51172
Lasa, L., Ayuso-Mateos, J. L., Vázquez-Barquero, J. L., Dıez-Manrique, F., & Dowrick, C. F. (2000). The use of the Beck Depression Inventory to screen for depression in the general population: a preliminary analysis.
Journal of affective disorders,
57(1-3), 261-265. DOI:
10.1016/s0165-0327(99)00088-9
Lunde, H. M. B., Assmus, J., Myhr, K.-M., Bø, L., & Grytten, N. (2017). Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study.
Journal of Neurology, Neurosurgery & Psychiatry,
88(8), 621-625. DOI:
10.1136/jnnp-2016-315238
Lovaei, P., Moradi, A., Taher, M., & Mikaeili, N. (2022). The effectiveness of memory-specificity training on emotion regulation and treatment adherence in cancer patients. Clinical Psychology, 14(4), 89–105.
https://doi.org/10.22075/jcp.2022.26219.2388
Marrie, R. A., Reingold, S., Cohen, J., Stuve, O., Trojano, M., Sorensen, P. S., Cutter, G., & Reider, N. (2015). The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. Multiple Sclerosis Journal, 21(3), 305-317.
McGinley, M. P., Goldschmidt, C. H., & Rae-Grant, A. D. (2021). Diagnosis and treatment of multiple sclerosis: a review.
Jama,
325(8), 765-779. DOI:
10.1001/jama.2020.26858
Menzin, J., Caon, C., Nichols, C., White, L. A., Friedman, M., & Pill, M. W. (2013). Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis.
Journal of managed care pharmacy,
19(1 Supp A), S24-S40.DOI:
10.18553/jmcp.2013.19.s1.S24
Niroomand, Dehnavi, R., Far, A., & Masoud. (2022). Effectiveness of cognitive rehabilitation using Captain Log software on executive functions in patients with multiple sclerosis. Neuropsychology, 8(29), 73–82.
https://doi.org/10.30473/clpsy.2021.60525.1618
Omranifard, V., Ebrahimi, A., Basti, T., Sharabafchi, M., Sajadiyeh, Sh., & Mortazavi, M. (2017). Investigating the relationship between treatment adherence and depression, anxiety, and coping strategies in kidney transplant patients.
Journal of Isfahan Medical School, 34(409), 1430–1438.
https://jims.mui.ac.i/article_15106_a252b52e7817e7462d1874e44754cfa6.pdf
Oliveira-Filho, A. D., Barreto-Filho, J. A., Neves, S. J. F., & Lyra Junior, D. P. d. (2012). Association between the 8-item Morisky Medication Adherence Scale (MMAS-8) and blood pressure control.
Arquivos brasileiros de cardiologia,
99, 649-658. DOI:
10.1590/s0066-782x2012005000053
Peyser, J. M., Edwards, K. R., Poser, C. M., & Filskov, S. B. (1980). Cognitive function in patients with multiple sclerosis.
Archives of neurology,
37(9), 577-579.DOI:
10.1001/archneur.1980.00500580073013
Pham, T., Jetté, N., Bulloch, A. G., Burton, J. M., Wiebe, S., & Patten, S. B. (2018). The prevalence of anxiety and associated factors in persons with multiple sclerosis.
Multiple sclerosis and related disorders,
19, 35-39. DOI:
10.1016/j.msard.2017.11.003
Rao, S. M., Leo, G. J., Bernardin, L., & Unverzagt, F. (1991). Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction.
Neurology,
41(5), 685-691.DOI:
10.1212/wnl.41.5.685
Remington, G., Rodriguez, Y., Logan, D., Williamson, C., & Treadaway, K. (2013). Facilitating medication adherence in patients with multiple sclerosis.
International journal of MS care,
15(1), 36-45.DOI:
10.7224/1537-2073.2011-038
Río, J., Porcel, J., Téllez, N., Sánchez-Betancourt, A., Tintoré, M. a., Arévalo, M. J., Nos, C., & Montalban, X. (2005). Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis.
Multiple Sclerosis Journal,
11(3), 306-309. DOI:
10.1191/1352458505ms1173oa
Sakaki, S., Naderi, F., & Hafezi, F. (2023). The causal relationship of depression with health-related quality of life through the mediating chain of chronic fatigue and treatment adherence in women with uterine cancer. Applied Family Therapy, 4(1), 512–533.
https://doi.org/10.22034/aftj.2023.336847.1520
Shafer, A. B. (2006). Meta‐analysis of the factor structures of four depression questionnaires: Beck, CES‐D, Hamilton, and Zung.
Journal of clinical psychology,
62(1), 123-146.DOI:
10.1002/jclp.20213
Steinberg, S. C., Faris, R. J., Chang, C. F., Chan, A., & Tankersley, M. A. (2010). Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study.
Clinical drug investigation,
30, 89-100.DOI:
10.2165/11533330-000000000-00000
Summers, M., Swanton, J., Fernando, K., Dalton, C., Miller, D., Cipolotti, L., & Ron, M. (2008). Cognitive impairment in multiple sclerosis can be predicted by imaging early in the disease.
Journal of Neurology, Neurosurgery & Psychiatry,
79(8), 955-958. DOI:
10.1136/jnnp.2007.138685
Tan, X., Patel, I., & Chang, J. (2014). Review of the four item Morisky medication adherence scale (MMAS-4) and eight item Morisky medication adherence scale (MMAS-8).
INNOVATIONS in pharmacy,
5(3), 5.DOI:
https://doi.org/10.24926/iip.v5i3.347